Studies on CCR5 activation during prostate cancer metastasis in mouse models and treatment with two small molecule inhibitors of CCR5 originally designed for HIV-1 therapy Maraviroc and Vicriviroc, which are CCR5 antagonists, reduced the tumour burden in both the bones and prostate [261]. The gene discussed is CCR5; the disease is prostate cancer.